Levetiracetam ratiopharm

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
26-06-2023
Karakteristik produk Karakteristik produk (SPC)
26-06-2023

Bahan aktif:

levetiracetam

Tersedia dari:

ratiopharm GmbH

Kode ATC:

N03AX14

INN (Nama Internasional):

levetiracetam

Kelompok Terapi:

Antiepileptics,

Area terapi:

Epilepsy

Indikasi Terapi:

Levetiracetam ratiopharm is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam ratiopharm is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ringkasan produk:

Revision: 15

Status otorisasi:

Authorised

Tanggal Otorisasi:

2011-08-26

Selebaran informasi

                                85
B. PACKAGE LEAFLET
86
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
_ _
LEVETIRACETAM RATIOPHARM 250 MG FILM-COATED TABLETS
LEVETIRACETAM RATIOPHARM 500 MG FILM-COATED TABLETS
LEVETIRACETAM RATIOPHARM 750 MG FILM-COATED TABLETS
LEVETIRACETAM RATIOPHARM 1000 MG FILM-COATED TABLETS
levetiracetam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START
TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Levetiracetam ratiopharm is and what it is used for
2.
What you need to know before you take Levetiracetam ratiopharm
3.
How to take Levetiracetam ratiopharm
4.
Possible side effects
5.
How to store Levetiracetam ratiopharm
6.
Contents of the pack and other information
1.
WHAT LEVETIRACETAM RATIOPHARM IS AND WHAT IT IS USED FOR
Levetiracetam is an antiepileptic medicine (a medicine used to treat
seizures in epilepsy).
Levetiracetam ratiopharm is used:
•
on its own in adults and adolescents from 16 years of age with newly
diagnosed epilepsy, to
treat a certain form of epilepsy. Epilepsy is a condition where the
patients have repeated fits
(seizures). Levetiracetam is used for the epilepsy form in which the
fits initially affect only one
side of the brain, but could thereafter extend to larger areas on both
sides of the brain (partial
onset seizure with or without secondary generalisation). Levetiracetam
has been given to you by
your doctor to reduce the number of fits.
•
as an add-on to other antiepileptic medicines to treat:
■
partial onset seizures with or without generalisation in adults,
adolescents, children and
infants from one mon
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Levetiracetam ratiopharm 250 mg film-coated tablets
Levetiracetam ratiopharm 500 mg film-coated tablets
Levetiracetam ratiopharm 750 mg film-coated tablets
Levetiracetam ratiopharm 1000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Levetiracetam ratiopharm 250 mg film-coated tablets
Each film-coated tablet contains 250 mg levetiracetam.
Levetiracetam ratiopharm 500 mg film-coated tablets
Each film-coated tablet contains 500 mg levetiracetam.
Levetiracetam ratiopharm 750 mg film-coated tablets
Each film-coated tablet contains 750 mg levetiracetam.
Levetiracetam ratiopharm 1000 mg film-coated tablets
Each film-coated tablet contains 1000 mg levetiracetam.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Levetiracetam ratiopharm 250 mg film-coated tablets
The 250 mg film-coated tablets are blue, oblong and scored on one
side.
Levetiracetam ratiopharm 500 mg film-coated tablets
The 500 mg film-coated tablets are yellow, oval and scored on one
side.
Levetiracetam ratiopharm 750 mg film-coated tablets
The 750 mg film-coated tablets are light red, oblong and scored on
both sides.
Levetiracetam ratiopharm 1000 mg film-coated tablets
The 1000 mg film-coated tablets are white, oblong and scored on both
sides.
The tablets can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Levetiracetam ratiopharm is indicated as monotherapy in the treatment
of partial onset seizures with or
without secondary generalisation in adults and adolescents from 16
years of age with newly diagnosed
epilepsy.
Levetiracetam ratiopharm is indicated as adjunctive therapy
•
in the treatment of partial onset seizures with or without secondary
generalisation in adults,
adolescents, children and infants from 1 month of age with epilepsy.
•
in the treatment of myoclonic seizures in adults and adolescents from
12 years of age with
Juvenile Myoclonic Epilepsy.
3
•
in t
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 26-06-2023
Karakteristik produk Karakteristik produk Bulgar 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 03-09-2021
Selebaran informasi Selebaran informasi Spanyol 26-06-2023
Karakteristik produk Karakteristik produk Spanyol 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 03-09-2021
Selebaran informasi Selebaran informasi Cheska 26-06-2023
Karakteristik produk Karakteristik produk Cheska 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 03-09-2021
Selebaran informasi Selebaran informasi Dansk 26-06-2023
Karakteristik produk Karakteristik produk Dansk 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 03-09-2021
Selebaran informasi Selebaran informasi Jerman 26-06-2023
Karakteristik produk Karakteristik produk Jerman 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 03-09-2021
Selebaran informasi Selebaran informasi Esti 26-06-2023
Karakteristik produk Karakteristik produk Esti 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 03-09-2021
Selebaran informasi Selebaran informasi Yunani 26-06-2023
Karakteristik produk Karakteristik produk Yunani 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 03-09-2021
Selebaran informasi Selebaran informasi Prancis 26-06-2023
Karakteristik produk Karakteristik produk Prancis 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 03-09-2021
Selebaran informasi Selebaran informasi Italia 26-06-2023
Karakteristik produk Karakteristik produk Italia 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 03-09-2021
Selebaran informasi Selebaran informasi Latvi 26-06-2023
Karakteristik produk Karakteristik produk Latvi 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 03-09-2021
Selebaran informasi Selebaran informasi Lituavi 26-06-2023
Karakteristik produk Karakteristik produk Lituavi 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 03-09-2021
Selebaran informasi Selebaran informasi Hungaria 26-06-2023
Karakteristik produk Karakteristik produk Hungaria 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 03-09-2021
Selebaran informasi Selebaran informasi Malta 26-06-2023
Karakteristik produk Karakteristik produk Malta 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 03-09-2021
Selebaran informasi Selebaran informasi Belanda 26-06-2023
Karakteristik produk Karakteristik produk Belanda 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 03-09-2021
Selebaran informasi Selebaran informasi Polski 26-06-2023
Karakteristik produk Karakteristik produk Polski 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 03-09-2021
Selebaran informasi Selebaran informasi Portugis 26-06-2023
Karakteristik produk Karakteristik produk Portugis 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 03-09-2021
Selebaran informasi Selebaran informasi Rumania 26-06-2023
Karakteristik produk Karakteristik produk Rumania 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 03-09-2021
Selebaran informasi Selebaran informasi Slovak 26-06-2023
Karakteristik produk Karakteristik produk Slovak 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 03-09-2021
Selebaran informasi Selebaran informasi Sloven 26-06-2023
Karakteristik produk Karakteristik produk Sloven 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 03-09-2021
Selebaran informasi Selebaran informasi Suomi 26-06-2023
Karakteristik produk Karakteristik produk Suomi 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 03-09-2021
Selebaran informasi Selebaran informasi Swedia 26-06-2023
Karakteristik produk Karakteristik produk Swedia 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 03-09-2021
Selebaran informasi Selebaran informasi Norwegia 26-06-2023
Karakteristik produk Karakteristik produk Norwegia 26-06-2023
Selebaran informasi Selebaran informasi Islandia 26-06-2023
Karakteristik produk Karakteristik produk Islandia 26-06-2023
Selebaran informasi Selebaran informasi Kroasia 26-06-2023
Karakteristik produk Karakteristik produk Kroasia 26-06-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 03-09-2021

Peringatan pencarian terkait dengan produk ini